Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2018-11-28 Regulatory Filings
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia avser att kalla till extra bolagsstämma efter begäran av en av de större aktieägarna i bolaget, som utan grund hävdar rätt till teckningsoptioner 2018/2019
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Oasmia intends to call an Extraordinary General Meeting (EGM) following a request from a major shareholder regarding a dispute over warrants and board composition. The core subject is the intention to hold a shareholder meeting and the underlying corporate governance/shareholder dispute. This relates directly to shareholder voting and meeting procedures. While it announces a future meeting, the immediate context is the corporate action leading to the meeting, which often involves proxy or governance materials. However, the most specific category for announcements related to shareholder votes or meetings, especially when involving disputes or calls for meetings, is often related to governance or voting. Since the text explicitly states the intent to call an 'extra bolagsstämma' (Extraordinary General Meeting) to potentially appoint a new board due to a shareholder dispute, this strongly points towards shareholder meeting/voting matters. Given the options, 'AGM-R' (AGM Information) is the closest fit for general meeting materials, even though this is an EGM announcement leading up to it. Alternatively, it could be seen as a general regulatory announcement (RNS) or a governance/proxy issue (DEF 14A/PSI). Since the primary action announced is the calling of a shareholder meeting (EGM), and the closest available code for meeting materials is AGM-R, I will select that, recognizing it's an announcement *about* a meeting rather than the final materials. Given the nature of the dispute and the call for a meeting, it is a significant corporate governance event. If the document were the actual notice or proxy statement, PSI or DEF 14A would be better. As it is an announcement about the *need* to call a meeting due to a shareholder request, it fits best under the general umbrella of shareholder meeting activity (AGM-R) or a general regulatory filing (RNS). Given the specific mention of calling a general meeting, AGM-R is the most targeted classification among the choices for meeting-related events.
2018-11-28 Swedish
Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
Earnings Release Classification · 99% confidence The document is a press release dated November 22, 2018, announcing that the European Commission has granted marketing authorization for the drug Apealea. It details the approval scope, clinical trial data (OAS-07OVA study results like PFS and OS), and provides background information on the drug and the disease. This type of announcement, focusing on a significant corporate event (regulatory approval) and providing key financial/operational data highlights, aligns best with an Earnings Release (ER) if it were quarterly results, but since it is a specific corporate event announcement that is not a standard financial report (10-K, IR, MRQ), it falls under general corporate news. However, given the options, it is a significant corporate announcement. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR). It is a press release announcing a major business development. Since there is no specific category for 'Regulatory Approval Announcement' outside of financial reporting contexts, and it is not a standard financial filing, it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if we interpret 'Earnings Release' broadly as 'Periodical/Key Result Announcement'. Given the content is a specific, non-periodic, material event announcement (drug approval), RNS (Regulatory Filings/Miscellaneous) is the most appropriate fallback, as ER usually pertains to revenue/profit figures. The document ends with a note about being obliged to make public pursuant to the EU Market Abuse Regulation, confirming its nature as a regulatory disclosure. FY 2018
2018-11-22 English
Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
Regulatory Filings Classification · 95% confidence The document is dated 2018-11-22 and is explicitly titled "PRESS RELEASE". It announces a significant corporate event: the European Commission granting marketing authorization for the drug Apealea®. This type of announcement, detailing regulatory milestones, clinical data summaries, and product updates, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing a major regulatory approval and includes key clinical data points (PFS, OS), it fits best under the Earnings Release (ER) category, which often encompasses major operational and regulatory news outside of formal quarterly reports (IR) or annual reports (10-K). It is not a transcript (CT), a formal financial report (IR/10-K), or a notice of dividend (DIV). Given the context of a major drug approval announcement, ER is the most appropriate fit among the provided options for a significant, time-sensitive corporate update.
2018-11-22 English
Oasmia Pharmaceutical AB får godkännande av Europeiska kommissionen för Apealea® (paklitaxel micellär)
Regulatory Filings Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces that Oasmia Pharmaceutical AB received approval from the European Commission for its drug Apealea®. It details the scope of the approval (EU countries, indication, combination therapy) and references clinical trial data (OAS-07OVA study results). The final paragraph explicitly states: "Denna information är sådan information som Oasmia Pharmaceutical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is information that Oasmia Pharmaceutical AB is obliged to disclose pursuant to the EU Market Abuse Regulation). This structure—a formal announcement of a significant regulatory event (drug approval) mandated by market regulations—is characteristic of a general regulatory filing or announcement, rather than a comprehensive financial report (10-K, IR) or a specific management/governance document. Since it is a mandatory disclosure under market abuse rules that doesn't fit perfectly into the other specific categories (like DIV, DIRS, or ER), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The document length (4450 chars) is short enough that it is an announcement, not the full regulatory submission itself.
2018-11-22 Swedish
New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
Regulatory Filings Classification · 95% confidence The document is a press release from Oasmia Pharmaceutical AB announcing that the USPTO has issued a notification of allowance for a patent related to their nanotech formulation method. It details the significance of the patent, its coverage, and its validity period. The text concludes with contact information, boilerplate 'About' information, and a mandatory statement regarding EU Market Abuse Regulation compliance, followed by an attachment link. This structure strongly suggests a formal regulatory announcement that is not a full financial report (like 10-K or IR) or a management change (MANG). Since it announces a specific legal/intellectual property event (patent allowance), it fits best under 'Legal Proceedings Report' (LTR) if the scope is broad enough to include IP protection milestones, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the specific nature of patent protection news, LTR is a strong candidate, but since it is an announcement of a positive legal/IP event rather than a lawsuit or regulatory action against the company, and it is a general press release format, RNS (Regulatory Filings - the fallback for miscellaneous announcements) is often used for such specific, non-financial, non-management updates. However, looking closely at the definitions, LTR is for 'Legal Proceedings Report' (lawsuits, regulatory actions). A patent allowance is a positive IP development. Since there is no specific category for 'Intellectual Property Update', and it is a formal announcement of a regulatory/legal milestone, RNS is the most appropriate general regulatory filing category, especially given the short length (3528 chars) and the presence of an attachment link, suggesting it's an announcement of information rather than the full detailed report itself.
2018-11-20 English
New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the USPTO has issued a notification of allowance for a new U.S. patent related to Oasmia Pharmaceutical's nanotechnology platform XR17. It details the patent's scope (a method of production for pharmaceutical formulations) and its implications for licensing and development. This type of announcement, focusing on intellectual property grants and their strategic impact, does not fit neatly into the defined categories like Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). Since it is a specific, material announcement that doesn't match the primary financial or corporate governance filings, the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal public disclosure of a significant regulatory/legal event (patent grant notification). It is not an AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is a general regulatory/legal update.
2018-11-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.